Correction to: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

In the article by Grundy et al, “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines,” which published ahead of print on November 10, 2018, and appears in the June 18/25, 2019, issue of the journal (Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625), several corrections were needed. 1. On page e1084, in the section “Top 10 Take-Home Messages to Reduce Risk of Atherosclerotic Cardiovascular Disease Through Cholesterol Management,” left column, Take Home Message 4: • The first sentence read, “4. In patients with severe primary hypercholesterolemia...begin high-intensity statin therapy without calculating 10-year ASCVD risk.” It has been updated to read, “4. In patients with severe primary hypercholesterolemia...without calculating 10-year ASCVD risk, begin high-intensity statin therapy.” • The third sentence read, “If the LDL-C level on statin plus ezetimibe...and economic value is low at mid-2018 list prices.” It has been updated to read, “If the LDL-C level on statin plus ezetimibe...and economic value is uncertain at mid-2018 list prices.” 2. On page e1089, in the section “2.2. Measurements of LDL-C and Non– HDL-C,” recommendation table: • Recommendation 2 read, “2. In adults who are 20 years of age or older and in whom an initial nonfasting lipid profile reveals a triglycerides level of 400 mg/dL (≥4.5 mmol/L) or higher, a repeat lipid profile in the fasting state should be performed for assessment of fasting triglyceride levels and baseline LDL-C.” It has been updated to read, “2. In adults who are 20 years of age or older and in whom an initial nonfasting lipid profile reveals a triglycerides level of 400 mg/dL or higher (≥4.5 mmol/L), a repeat lipid profile in the fasting state should be performed for assessment of fasting triglyceride levels and baseline LDL-C.” • Recommendation 3 read, “3. For patients with an LDL-C level less than 70 mg/dL (<1.8 mmol/L), measurement of direct LDL-C or modified LDL-C estimate is reasonable to improve accuracy over the Friedewald formula.” It has been updated to read, “3. For adults with an LDL-C level less than 70 mg/dL (<1.8 mmol/L), measurement of direct LDL-C or modified LDL-C estimate is reasonable to improve accuracy over the Friedewald formula.” 3. On pages e1091–e1092, in the section “4.1. Secondary ASCVD Prevention,” recommendation table: • Recommendation 4 read, “4. In patients with clinical ASCVD who are judged to be very high risk and who are on maximally tolerated LDL-C © 2019 American Heart Association, Inc. Circulation